[Federal Register Volume 71, Number 45 (Wednesday, March 8, 2006)]
[Notices]
[Page 11671]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-3267]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Government-Owned Inventions; Availability for Licensing and 
Cooperative Research and Development Agreements (CRADAs)

AGENCY: Centers for Disease Control and Prevention Technology Transfer 
Office; Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention named in this notice is owned by agencies of the 
United States Government and is available for licensing in the United 
States (U.S.) in accordance with 35 U.S.C. 207, and is available for 
cooperative research and development agreements (CRADAs) in accordance 
with 15 U.S.C. 3710a, to achieve expeditious commercialization of 
results of federally funded research and development. A provisional 
patent application has been filed. A Patent Cooperation Treaty (PCT) 
application and national stage foreign patent applications claiming 
priority to the Patent Cooperation Treaty (PCT) application are 
expected to be filed within the appropriate deadlines to extend market 
coverage for U.S. companies and may also be available for licensing.

ADDRESSES: Licensing and CRADA information, and information related to 
the technology listed below, may be obtained by writing to Suzanne 
Seavello Shope, J.D., Technology Licensing and Marketing Scientist, 
Technology Transfer Office, Centers for Disease Control and Prevention 
(CDC), Mailstop K-79, 4770 Buford Highway, Atlanta, GA 30341, telephone 
(770)488-8613; facsimile (770)488-8615; or e-mail [email protected]. A 
signed Confidential Disclosure Agreement (available under Forms at 
http://www.cdc.gov/tto) will be required to receive copies of 
unpublished patent applications and other information.

Diagnostics

Immunoassay for Diagnosis of Orthopoxvirus Infection

    A CDC-developed immunoassay may be used for the diagnosis of 
infection with Orthopoxviruses (e.g. Monkeypox, Variola) by detection 
of acute phase immune responses that correlate to recent infection. 
With recent recognition of Orthopox viruses as emerging infectious 
agents with zoonotic transmission capabilities as well as select agents 
for bioterrorism, assays for the detection or diagnosis of infections 
are sought. This assay provides a rapid and simple method for detection 
of infection with these viruses related to zoonotic transmission or 
bioterrorism events involving such viruses.
    Use of the assay produced high levels of sensitivity during the 
2003 Monkeypox outbreak in North America when compared to PCR. 
Commercialization of the ELISA test may provide a standard screening 
tool for diagnosis of Orthopoxvirus as well as a surveillance tool for 
exposure.
    The immunoassay may also be useful at the state level for BT 
surveillance including an opportunity for use in reference labs. 
Reagents used in the assay are available through CDC laboratories and 
for commercial development of the assay. Further refinement of the 
assay may result in the development of additional reagents for 
incorporation into the assay.
    Inventors: Kevin L. Karem, Inger K. Damon and Joanne L. Patton.
    CDC Ref. #: I-014-04.

James D. Seligman,
Chief Information Officer, Centers for Disease Control and Prevention.
[FR Doc. E6-3267 Filed 3-7-06; 8:45 am]
BILLING CODE 4163-18-P